# Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma

> **NCT02786641** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 235 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Cisplatin 1
- **DRUG:** Xeloda
- **RADIATION:** IMRT
- **DRUG:** Cisplatin 2

## Key facts

- **NCT ID:** NCT02786641
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2018-08
- **Final completion:** 2021-08
- **Target enrollment:** 235 (ESTIMATED)
- **Last updated:** 2016-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02786641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02786641, "Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02786641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*